Anthropometric Measurements as Predictors of Low Birth Weight Among Tanzanian Neonates: A Hospital-Based Study
November 7, 2025
Brand Name :
Entereg
Synonyms :
alvimopan
Class :
Peripheral opioid receptor antagonists
Dosage Forms & Strengths
Capsule
12mg
GI Recovery Post Bowel Resection
12 mg orally administer 30 minutes-5 hours preoperative
Following 12 mg orally every 12 hours beginning 1 day after surgery for 7 days
Do not exceed more than 15 doses.
may have an increasingly adverse effect when combined with alvimopan
may have an increasingly adverse effect when combined with alvimopan
may have an increasingly adverse effect when combined with alvimopan
may have an increasingly adverse effect when combined with alvimopan
alvimopan: it may increase the risk of CNS depression
alvimopan: it may increase the risk of CNS depression
alvimopan: it may increase the risk of CNS depression
may increase the effect of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effects of opioid agonists
may increase the toxic effect
may increase the toxic effect of opioid agonists
may increase the adverse effect of Opioid Agonists
buprenorphine,long-acting injection
may increase the adverse effect of Opioid Agonists
alvimopan: it may increase the risk of methemoglobinemia agents
alvimopan: it may increase the risk of methemoglobinemia agents
alvimopan: it may increase the risk of methemoglobinemia agents
alvimopan: it may increase the risk of methemoglobinemia agents
alvimopan: it may increase the risk of methemoglobinemia agents
may enhance the risk of adverse/toxic effect of alvimopan
may enhance the risk of adverse/toxic effect of alvimopan
may enhance the risk of adverse/toxic effect of alvimopan
alvimopan: they may enhance the serum concentration of CYP2D6 Inhibitors
alvimopan: they may enhance the serum concentration of CYP2D6 Inhibitors
alvimopan: they may enhance the serum concentration of CYP2D6 Inhibitors
alvimopan: they may enhance the serum concentration of CYP2D6 Inhibitors
alvimopan: they may enhance the serum concentration of CYP2D6 Inhibitors
alvimopan: it may increase the risk or severity of CNS depression
alvimopan: it may increase the risk or severity of CNS depression
alvimopan: it may increase the risk or severity of CNS depression
alvimopan: it may increase the risk or severity of CNS depression
alvimopan: it may increase the risk or severity of CNS depression
the risk or extent of adverse effects can be raised when oxycodone is combined with alvimopan
the risk of adverse effects may be increased
Adverse drug reactions
Frequency Defined
1-10%
Flatulence (8.7%)
Dyspepsia (7%)
Anemia (5.4%)
Constipation (10%)
Hypokalemia (9.5%)
Back pain (3.4%)
Pregnancy warnings:
US FDA pregnancy category: Not assigned
Lactation:
Excreted into human milk is unknown
Pregnancy Categories:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: No evidence shown of risk to the fetus found in animal reproduction studies, and there are not enough studies on pregnant women
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for a result in humans must take care of potential risks in pregnant women
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient Information Leaflet
Generic Name: alvimopan
Why do we use alvimopan?
alvimopan is a Peripheral opioid receptor antagonists used for GI Recovery Post Bowel Resection.